Clinic will allow researchers to conduct twice as many immunotherapy trials, enable intensive patient monitoring to improve experimental therapies.

Fred Hutchinson Cancer Research Center on Tuesday announced the official opening of a first-of-its-kind clinic dedicated to providing immunotherapies for cancer patients in clinical trials.

The Bezos Family Immunotherapy Clinic, named in recognition of a family that has been deeply committed to the Hutch and its work to advance immunotherapy, will allow researchers to conduct twice as many immunotherapy trials in the next year.

Roche’s Genentech has received FDA approval for an immunotherapy targeting the highly sought-after PD-L1. The treatment may be able to outperform its competitors in lung cancer therapies.

roche logoIn May, Roche received approval for Tecentriq (atezolizumab) in bladder cancer. Now, the drug is expanding its indications to become the first and only cancer immunotherapy in the market to target the checkpoint inhibitor Program-Death ligand 1 (PD-L1) in metastatic non-small cell lung cancer (NSCLC)

When injected into the body, Tumor Paint lights up cancers. The drug could lead to a new class of therapeutics


To make Tumor Paint, Jim Olson's team extracts molecules from the deathstalker scorpion (Leiurus quinquestriatus).(Wikipedia)

By Nathan Hurst


On Sunday at the European Society of Medical Oncology (ESMO) 2016 Congress, Merck revealed results of two clinical trials that treated lung cancer patients with immunotherapy and could pave the way for its use as a first-line treatment option. In both trials, patients with metastatic and previously untreated non-small cell lung carcinoma (NSCLC) benefited from treatment with checkpoint blockade using the anti-PD-1 drug pembrolizumab. The results from the trials were published in the New England Journal of Medicine and The Lancet

Go to top
JSN Boot template designed by